About AcuamarkDx
AcuamarkDx is a Healthcare company based in New York (United States) founded in 2013. Non-invasive screening tests for early cancer detection are provided. AcuamarkDx has raised $20.01 million across 4 funding rounds from investors including Bruker and Claudio Del Vecchio. AcuamarkDx offers products and services including qPCR Cancer Assay. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is ACUAMARK DIAGNOSTICS, INC. Its competitors include Guardant Health, GRAIL and Delfi Diagnostics; 3 of its 3 listed competitors have raised funding.
Company details
Provider of non-invasive screening test for early detection of cancer. The proprietary Eagle iSEQ is a deep sequencing analytic tool that enables targeted deep sequencing of DNA from blood and is compatible with existing instrumentation. The Eagle i5 suite of assays detects multiple cancer markers, including gene mutation, methylation, exosomal miRNA, lncRNA and mRNA, translocations, and splice variants. The first application is colorectal cancer, but the company plans to expand to a pan-cancer assay.
- Headquarters New York, United States
- SectorsHealthcare
- Email••••••••
- Website acuamarkdx.com
- Social LinkedIn X Facebook Instagram
- Legal Name Acuamark Diagnostics, Inc.
- Total Equity Funding$20.01M (USD)
in 4 rounds
- Latest Funding Round$4.94M (USD), Series A
May 2024
- InvestorsBruker
& 1 more
Products & Services of AcuamarkDx
AcuamarkDx offers a comprehensive portfolio of products and services, including qPCR Cancer Assay.
Technology for detecting early-stage cancer markers in blood samples.
Funding Insights of AcuamarkDx
AcuamarkDx has successfully raised a total of $20.01M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $4.94 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20.01M
- Total Rounds 4
- Last Round Series A — $4.94M
- First Round $1.48M
(Nov 2016)
- Investors Count 2
All 4 funding rounds of AcuamarkDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $4.94M | Series A | – | – | – |
| Jul 2022 | $11.3M | Series A | – | Claudio Del Vecchio | |
| Sep 2019 | $2.29M | Seed | – | – | – |
| Nov 2016 | $1.48M | Seed | – | – | – |
2 investors in total: 1 institutional and 1 angel.
Investors in AcuamarkDx
AcuamarkDx has secured backing from 2 investors, including angel and institutional investors. Prominent investors backing the company include Bruker and Claudio Del Vecchio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified research instrument systems are manufactured and supplied. | 1960 | bruker.com | United States | |
CD Claudio Del Vecchio | unknown_3622838c14bf459d8 |
Investor details for AcuamarkDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of AcuamarkDx
3 dated milestones of AcuamarkDx across 11 years, from founding to its latest funding, stage changes and deals.
- Founded AcuamarkDx is founded.
- Funding First funding round of $1.5M.
- Funding Latest funding round, Series A, of $4.9M.
Competitors of AcuamarkDx
AcuamarkDx has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, GRAIL and Delfi Diagnostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| delfidiagnostics.com | 2019 | Baltimore, United States | $331.59M | Provider of DNA sequencing for cancer detection |
Detailed competitors of AcuamarkDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AcuamarkDx
The website of AcuamarkDx (acuamarkdx.com) receives about 1K visits a month.
- Monthly visits1K
▼ 25.4% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as AcuamarkDx (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Acuamarkdx
Complete news archive for AcuamarkDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AcuamarkDx
AcuamarkDx was founded in 2013 and raised its 1st funding round 3 years after it was founded.
AcuamarkDx is headquartered in New York, United States. It is registered at New York, New York, United States.
AcuamarkDx is a funded company, having raised a total of $20.01M across 4 funding rounds to date. The company's 1st funding round was a Seed of $1.48M, raised on Nov 2016.
Provider of non-invasive screening test for early detection of cancer. The proprietary Eagle iSEQ is a deep sequencing analytic tool that enables targeted deep sequencing of DNA from blood and is compatible with existing instrumentation. The Eagle i5 suite of assays detects multiple cancer markers, including gene mutation, methylation, exosomal miRNA, lncRNA and mRNA, translocations, and splice variants. The first application is colorectal cancer, but the company plans to expand to a pan-cancer assay.
AcuamarkDx's top competitors include Guardant Health, GRAIL and Delfi Diagnostics.
AcuamarkDx offers qPCR Cancer Assay.
AcuamarkDx has 2 investors. Key investors include Bruker, and Claudio Del Vecchio.
AcuamarkDx operates through Acuamark Diagnostics, Inc..